Logo image of 2EM.DE

ERGOMED PLC (2EM.DE) Stock Price, Quote, News and Overview

FRA:2EM - Deutsche Boerse Ag - GB00BN7ZCY67 - Common Stock - Currency: EUR

11  -0.42 (-3.68%)

2EM.DE Quote, Performance and Key Statistics

ERGOMED PLC

FRA:2EM (3/31/2023, 7:00:00 PM)

11

-0.42 (-3.68%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High18.95
52 Week Low11
Market Cap558.54M
Shares50.78M
Float40.59M
Yearly DividendN/A
Dividend YieldN/A
PE33.33
Fwd PE20.66
Earnings (Next)N/A N/A
IPO07-15 2014-07-15


2EM.DE short term performance overview.The bars show the price performance of 2EM.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

2EM.DE long term performance overview.The bars show the price performance of 2EM.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of 2EM.DE is 11 EUR. In the past month the price decreased by -24.66%. In the past year, price decreased by -36.96%.

ERGOMED PLC / 2EM Daily stock chart

2EM.DE Competitors/Peers

The largest stocks on the EU markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TN8.DE THERMO FISHER SCIENTIFIC INC 17.93 128.71B
DAP.DE DANAHER CORP 26.04 120.59B
LO3.DE LONZA GROUP AG-REG 37.16 42.79B
56S1.DE SARTORIUS STEDIM BIOTECH 51.97 19.22B
DIM.PA SARTORIUS STEDIM BIOTECH 51.75 19.14B
SRT3.DE SARTORIUS AG-VORZUG 49.4 15.80B
SRT.DE SARTORIUS AG 39.86 12.74B
ILU.DE ILLUMINA INC 27.1 12.40B
ESF0.DE EUROFINS SCIENTIFIC 33.63 11.03B
ERF.PA EUROFINS SCIENTIFIC 32.94 10.80B
QIA.DE QIAGEN N.V. 20.41 8.79B
1SXP.DE SCHOTT PHARMA AG& CO KGAA 28.27 4.17B

About 2EM.DE

Company Profile

2EM logo image Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey and currently employs 1,255 full-time employees. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm serves over 100 countries. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.

Company Info

ERGOMED PLC

1 Occam Court, Occam Road

Guildford SURREY GB

Employees: 1255

2EM Company Website

Phone: 441483503205.0

ERGOMED PLC / 2EM.DE FAQ

What is the stock price of ERGOMED PLC today?

The current stock price of 2EM.DE is 11 EUR. The price decreased by -3.68% in the last trading session.


What is the ticker symbol for ERGOMED PLC stock?

The exchange symbol of ERGOMED PLC is 2EM and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is 2EM.DE stock listed?

2EM.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for ERGOMED PLC stock?

12 analysts have analysed 2EM.DE and the average price target is 16.93 EUR. This implies a price increase of 53.9% is expected in the next year compared to the current price of 11. Check the ERGOMED PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ERGOMED PLC worth?

ERGOMED PLC (2EM.DE) has a market capitalization of 558.54M EUR. This makes 2EM.DE a Small Cap stock.


How many employees does ERGOMED PLC have?

ERGOMED PLC (2EM.DE) currently has 1255 employees.


What are the support and resistance levels for ERGOMED PLC (2EM.DE) stock?

ERGOMED PLC (2EM.DE) has a support level at 10.99 and a resistance level at 11.43. Check the full technical report for a detailed analysis of 2EM.DE support and resistance levels.


Is ERGOMED PLC (2EM.DE) expected to grow?

The Revenue of ERGOMED PLC (2EM.DE) is expected to grow by 12.58% in the next year. Check the estimates tab for more information on the 2EM.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ERGOMED PLC (2EM.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ERGOMED PLC (2EM.DE) stock pay dividends?

2EM.DE does not pay a dividend.


What is the Price/Earnings (PE) ratio of ERGOMED PLC (2EM.DE)?

The PE ratio for ERGOMED PLC (2EM.DE) is 33.33. This is based on the reported non-GAAP earnings per share of 0.33 and the current share price of 11 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 2EM.DE.


2EM.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

2EM.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 2EM.DE. While 2EM.DE has a great health rating, its profitability is only average at the moment.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

2EM.DE Financial Highlights

Over the last trailing twelve months 2EM.DE reported a non-GAAP Earnings per Share(EPS) of 0.33. The EPS increased by 16.6% compared to the year before.


Industry RankSector Rank
PM (TTM) 10.31%
ROA 11.58%
ROE 17.68%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%23.7%
Sales Q2Q%20.48%
EPS 1Y (TTM)16.6%
Revenue 1Y (TTM)22.5%

2EM.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to 2EM.DE. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 15.11% and a revenue growth 12.58% for 2EM.DE


Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts85
Price Target16.93 (53.91%)
EPS Next Y15.11%
Revenue Next Year12.58%